Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool September 25, 2006 Brian Lawler	Merck's Positive Contribution Bad press from Vioxx shouldn't overshadow the company's new offering. Investors, take note.
The Motley Fool July 20, 2007 Brian Lawler	Glaxo Heats Up the Vaccine Battle GlaxoSmithKline's cervical cancer vaccine gets a positive recommendation in the EU. Sales could begin in early 2008 and will compete with Gardasil, by rival Merck.
The Motley Fool February 11, 2005 Stephen D. Simpson	Cytyc Grows but Stays Focused Still concentrating on women's health, the company looks to move beyond its traditional diagnostics business.
The Motley Fool July 7, 2009 Brian Orelli	Glaxo Missed the Boat The HPV vaccine market is declining before Glaxo can hop aboard.
The Motley Fool October 19, 2009 Brian Orelli	The HPV Vaccine Wars of 2010 Merck and GlaxoSmithKline human papillomavirus vaccines were both approved by the Food and Drug Administration for different indications.
The Motley Fool April 4, 2007 Brian Lawler	GlaxoSmithKline Gets Ready for the Vaccine Wars British pharmaceutical powerhouse GlaxoSmithKline submits a marketing application to the FDA for its HPV vaccine. Investors, take note.
The Motley Fool October 7, 2005 Brian Gorman	Merck's Tricky Sell A vaccine for human papillomavirus clears scientific hurdles, but marketing could prove its biggest obstacle.
The Motley Fool May 1, 2006 Stephen D. Simpson	Can Lab Corp Meet the Value Test? Here is a fine and well-run company, but not really a bargain for investors.
The Motley Fool February 2, 2006 Stephen D. Simpson	Cytyc Still Stands On Its Own Despite apparent doubts about some mergers, the med-tech company is still growing strongly. Investors, take note.
BusinessWeek November 29, 2004 Kerry Capell	"A Vaccine Every Woman Should Take" Two drug companies are closing in on shots against HPV, the leading cause of cervical cancer. Despite the obvious benefits, the vaccines may not be an easy sell: There are social and moral hurdles to overcome.
The Motley Fool July 1, 2008 Brian Lawler	FDA News Gives Glaxo a Glimmer of Hope Approval is delayed, but new studies won't be needed for Cervarix.
BusinessWeek August 27, 2009 Arlene Weintraub	Is Merck Overselling a Cancer Vaccine? Fresh controversies are heating up over the marketing of products to prevent cervical cancer.
The Motley Fool October 23, 2007 Brian Orelli	Old Merck on New Drugs It looks like the old Merck is back, with new drugs driving double-digit sales growth in the third-quarter.
The Motley Fool June 26, 2008 Brian Orelli	The FDA's Latest Victim Merck fails to get its Gardasil vaccine approved to treat older women.
The Motley Fool September 15, 2008 Brian Orelli	The Little Label Expansion That Couldn't Merck gets Gardasil approved to protect against other cancers, but don't expect it to increase usage very much.
The Motley Fool November 13, 2008 Brian Orelli	Merck Could Double Potential Customers Merck's HPV vaccine, Gardasil, which is now recommended for girls and women is also shown to benefit boys and men.
The Motley Fool September 28, 2007 Brian Orelli	Free Drugs From Merck Merck plans to donate enough of its Gardasil vaccine to vaccinate one million women, in some of the poorest countries in the world, against the human papilloma virus.
Pharmaceutical Executive May 1, 2006 Joanna Breitstein	Cervical Cancer: Endagered Species Preventive care is more efficient than treating disease after the fact. Now this paradigm takes hold in cancer with new HPV vaccines. Now that the science is in order, Merck and GSK face several important challenges in conditioning the market.
The Motley Fool January 31, 2007 Brian Gorman	Merck's Special Interest Merck is likely to succeed in getting states to mandate HPV vaccination. Still, investors shouldn't necessarily bet everything on Gardasil.
The Motley Fool November 13, 2007 Brian Orelli	Merck: Case Closed? Now that Merck has settled its lawsuit, it can get back to business, focusing on continued growth from its cholesterol drugs, new diabetic medication, and cervical cancer vaccine. Investors, take note.
The Motley Fool December 18, 2007 Brian Lawler	Cervarix Won't Save Glaxo Yet The FDA has another delay for this HPV vaccine. The agency has completed its review, but still has questions.
The Motley Fool September 10, 2009 Brian Orelli	The Vanishing Vaccine War And it had such potential to be a bloodbath.
The Motley Fool October 19, 2011 Brian Orelli	This High-Tech Company Still Has the Touch Intuitive Surgical beats analysts' expectations. Again.
BusinessWeek July 25, 2005 Gene G. Marcial	Is Merck Rallying After That Nasty Tumble? Although most analysts who track Merck remain bearish on the beleaguered drugmaker, some upbeat investors are buying. Why? It's Vioxx market may have softened, but its new vaccines will rise to the occasion.
The Motley Fool November 6, 2007 Brian Orelli	Getting Vaccinated Alongside Mom Merck presents data supporting use of its HPV vaccine in older women. The drugmaker may have a tough marketing job ahead of it.
Scientific American February 2006	To Banish a Cancer Two vaccines that are nearing approval by the Food and Drug Administration in the U.S. have demonstrated in clinical trials that they can prevent infection from the two types of the human papillomavirus (HPV) that account for up to 70 percent of cervical cancers.
Health October 10, 2008	Cervical Cancer FAQ Signs, symptoms, prevention, and treatments are some of the topics explained here.
The Motley Fool January 31, 2006 Stephen D. Simpson	Merck Marking Time There won't be much good news for this pharmaceutical's investors until new products hit the market. If you already own Merck, you probably understand that patience will be the order of the day here.
BusinessWeek May 23, 2005 Catherine Arnst	If It Works for Breast Cancer... Studies are under way to see if promising strategies used against breast cancer can be used to fight other killers, such as lung, colon, and prostate cancer.
American Journal of Nursing October 2010 Eileen Thomas	Men's Awareness and Knowledge of Male Breast Cancer This article reports on the findings of a qualitative study that explored the awareness and knowledge of male breast cancer among English-speaking men.
BusinessWeek July 3, 2006 Catherine Arnst	A Ton Of Prevention The pros and cons of two drugs that may halve your risk of breast cancer.
The Motley Fool April 7, 2005 Brian Gorman	Merck Soldiers On The drug company's experimental HPV treatment has significant potential. Investors should not overlook the company's positive developments.
American Family Physician October 1, 2000	Genetic Testing for Breast Cancer Risk: What Does It Mean to Me? What causes breast cancer?... What genes can cause breast cancer to be inherited?... What clues in my family history might show I've inherited a risk of breast cancer?... Does everyone who has family members with breast cancer have these mutated genes?... What should I do?...
The Motley Fool May 8, 2009 Brian Orelli	Glaxo Goes Head-to-Head on HPV Glaxo's data may not be enough to help Cervarix knock Merck's Gardasil from the top papillomavirus vaccine spot.
Pharmaceutical Executive February 1, 2007 Beth Herskovits	Brand of the Year A first annual Brand of the Year honor goes to Gardasil, Merck's breakthrough vaccine for human papillomavirus.
Managed Care June 2007 Thomas Morrow	Dendritic Cell Vaccine Hits FDA Roadblock Questions about study design and analysis prompted the FDA to postpone action on Provenge, a treatment for advanced prostate cancer.
AskMen.com Jacob Franek	New Cancer Therapies As cancer research explodes, the availability of new and innovative interventions is expanding almost daily.
Salon.com October 12, 1999 Damien Cave	Male mastectomy Not many men get breast cancer, but too few are aware of the risk.